These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 19666869)

  • 21. Comprehensive array CGH of normal karyotype myelodysplastic syndromes reveals hidden recurrent and individual genomic copy number alterations with prognostic relevance.
    Thiel A; Beier M; Ingenhag D; Servan K; Hein M; Moeller V; Betz B; Hildebrandt B; Evers C; Germing U; Royer-Pokora B
    Leukemia; 2011 Mar; 25(3):387-99. PubMed ID: 21274003
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeted next-generation sequencing in myelodysplastic syndromes and prognostic interaction between mutations and IPSS-R.
    Tefferi A; Lasho TL; Patnaik MM; Saeed L; Mudireddy M; Idossa D; Finke C; Ketterling RP; Pardanani A; Gangat N
    Am J Hematol; 2017 Dec; 92(12):1311-1317. PubMed ID: 28875545
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Overexpression of Arginase 1 is linked to DNMT3A and TET2 mutations in lower-grade myelodysplastic syndromes and chronic myelomonocytic leukemia.
    Cull AH; Mahendru D; Snetsinger B; Good D; Tyryshkin K; Chesney A; Ghorab Z; Reis M; Buckstein R; Wells RA; Rauh MJ
    Leuk Res; 2018 Feb; 65():5-13. PubMed ID: 29227812
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Novel TET2 mutations associated with UPD4q24 in myelodysplastic syndrome.
    Mohamedali AM; Smith AE; Gaken J; Lea NC; Mian SA; Westwood NB; Strupp C; Gattermann N; Germing U; Mufti GJ
    J Clin Oncol; 2009 Aug; 27(24):4002-6. PubMed ID: 19528370
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CXXC4 mRNA levels are associated with clinicopathological parameters and survival of myelodysplastic syndrome patients.
    Li S; Fan R; Zhao XL; Wang XQ
    Leuk Res; 2014 Sep; 38(9):1072-8. PubMed ID: 25085016
    [TBL] [Abstract][Full Text] [Related]  

  • 26. BCOR and BCORL1 mutations in myelodysplastic syndromes and related disorders.
    Damm F; Chesnais V; Nagata Y; Yoshida K; Scourzic L; Okuno Y; Itzykson R; Sanada M; Shiraishi Y; Gelsi-Boyer V; Renneville A; Miyano S; Mori H; Shih LY; Park S; Dreyfus F; Guerci-Bresler A; Solary E; Rose C; Cheze S; Prébet T; Vey N; Legentil M; Duffourd Y; de Botton S; Preudhomme C; Birnbaum D; Bernard OA; Ogawa S; Fontenay M; Kosmider O
    Blood; 2013 Oct; 122(18):3169-77. PubMed ID: 24047651
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The prognostic impact of tet oncogene family member 2 mutations in patients with acute myeloid leukemia: a systematic-review and meta-analysis.
    Wang R; Gao X; Yu L
    BMC Cancer; 2019 Apr; 19(1):389. PubMed ID: 31023266
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mutation in TET2 in myeloid cancers.
    Delhommeau F; Dupont S; Della Valle V; James C; Trannoy S; Massé A; Kosmider O; Le Couedic JP; Robert F; Alberdi A; Lécluse Y; Plo I; Dreyfus FJ; Marzac C; Casadevall N; Lacombe C; Romana SP; Dessen P; Soulier J; Viguié F; Fontenay M; Vainchenker W; Bernard OA
    N Engl J Med; 2009 May; 360(22):2289-301. PubMed ID: 19474426
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Consequences of mutant TET2 on clonality and subclonal hierarchy.
    Hirsch CM; Nazha A; Kneen K; Abazeed ME; Meggendorfer M; Przychodzen BP; Nadarajah N; Adema V; Nagata Y; Goyal A; Awada H; Asad MF; Visconte V; Guan Y; Sekeres MA; Olinski R; Jha BK; LaFramboise T; Radivoyevitch T; Haferlach T; Maciejewski JP
    Leukemia; 2018 Aug; 32(8):1751-1761. PubMed ID: 29795413
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Down-regulation of TET2 in CD3⁺ and CD34⁺ cells of myelodysplastic syndromes and enhances CD34⁺ cells proliferation.
    Zhang W; Shao Z; Fu R; Wang H; Li L; Liu H
    Int J Clin Exp Pathol; 2015; 8(9):10840-6. PubMed ID: 26617797
    [TBL] [Abstract][Full Text] [Related]  

  • 31. TET2 expression level and 5-hydroxymethylcytosine are decreased in refractory cytopenia of childhood.
    Coutinho DF; Monte-Mór BC; Vianna DT; Rouxinol ST; Batalha AB; Bueno AP; Boulhosa AM; Fernandez TS; Pombo-de-Oliveira MS; Gutiyama LM; Abdelhay E; Zalcberg IR
    Leuk Res; 2015 Oct; 39(10):1103-8. PubMed ID: 26277372
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mutation of ten-eleven translocation-2 is associated with increased risk of autoimmune disease in patients with myelodysplastic syndrome.
    Oh YJ; Shin DY; Hwang SM; Kim SM; Im K; Park HS; Kim JA; Song YW; Márquez A; Martín J; Lee DS; Park JK
    Korean J Intern Med; 2020 Mar; 35(2):457-464. PubMed ID: 31640337
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The prognostic impact of variant allele frequency (VAF) in TP53 mutant patients with MDS: A systematic review and meta-analysis.
    Deng J; Wu X; Ling Y; Liu X; Zheng X; Ye W; Gong Y
    Eur J Haematol; 2020 Nov; 105(5):524-539. PubMed ID: 32621334
    [TBL] [Abstract][Full Text] [Related]  

  • 34. TET2 mutations in acute myeloid leukemia (AML): results from a comprehensive genetic and clinical analysis of the AML study group.
    Gaidzik VI; Paschka P; Späth D; Habdank M; Köhne CH; Germing U; von Lilienfeld-Toal M; Held G; Horst HA; Haase D; Bentz M; Götze K; Döhner H; Schlenk RF; Bullinger L; Döhner K
    J Clin Oncol; 2012 Apr; 30(12):1350-7. PubMed ID: 22430270
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [The incidence of TET2 gene mutation and its clinical significance in acute myeloid leukemia patients].
    Wei JF; Chen GH; Qiu HY; Fu CC; Ding ZX; Liu H; Feng YF; Chen SN; Chang WR; Wu DP
    Zhonghua Xue Ye Xue Za Zhi; 2011 May; 32(5):304-7. PubMed ID: 21729597
    [TBL] [Abstract][Full Text] [Related]  

  • 36. TET2 rs2454206, TET2 rs12498609 and ASXL1 rs3746609 single nucleotide polymorphisms in patients with myelodysplastic syndromes.
    Hu J; Xu J; Tian T; Xie J; Fan L; Zhu G; Xia T; Chen X; Tan Y; Chen X; Ren F; Zhang Y; Wang H; Xu Z
    Blood Cells Mol Dis; 2019 Feb; 74():44-50. PubMed ID: 30454965
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Acute myeloid leukaemia: recent data on prognostic gene mutations, in relation to stratified therapies for elderly patients.
    Soura EN; Karikas GA
    J BUON; 2019; 24(4):1326-1339. PubMed ID: 31646775
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cryptic aberrations may allow more accurate prognostic classification of patients with myelodysplastic syndromes and clonal evolution.
    Svobodova K; Lhotska H; Hodanova L; Pavlistova L; Vesela D; Belickova M; Vesela J; Brezinova J; Sarova I; Izakova S; Lizcova L; Siskova M; Jonasova A; Cermak J; Michalova K; Zemanova Z
    Genes Chromosomes Cancer; 2020 Jul; 59(7):396-405. PubMed ID: 32170980
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic significance of SRSF2 mutations in myelodysplastic syndromes and chronic myelomonocytic leukemia: a meta-analysis.
    Arbab Jafari P; Ayatollahi H; Sadeghi R; Sheikhi M; Asghari A
    Hematology; 2018 Dec; 23(10):778-784. PubMed ID: 29757120
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Recent advances of molecular mechanisms influencing prognosis of myelodysplastic syndrome - review].
    Guo J; Chang CK; Li X
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Aug; 20(4):1020-4. PubMed ID: 22931676
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.